drugset / Trial / NCT04362111
Early Treatment of Cytokine Storm Syndrome in Covid-19
RandomizedParallel-groupTriple-blindTreatment
Summary
This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2021-12-31
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |